Market Overview

UPDATE: BMO Capital Markets Reiterates Market Perform Rating, Raises PT on Eli Lilly & Co.

Share:
Related LLY
Carl Icahn's Track Record In Big Pharma
After Merck Stops Study, What Remains Of The Alzheimer's Drug Pipeline?
Truxima Fires The Starting Gun In Biosimilar Race To The Bottom (Seeking Alpha)

In a report published Monday, BMO Capital Markets reiterated its Market Perform rating on Eli Lilly & Co. (NYSE: LLY), and raised its price target from $47.00 to $52.00.

BMO Capital Markets noted, “Eli Lilly provided financial guidance for 2013 and reconfirmed its mid-term guidance through 2014. The company reiterated its expectation to reach 2014 revenues of at least $20Bn and net income of at least $3Bn (consensus was $19.6Bn and $2.9Bn, respectively, on January 4, 2013). In 4Q12, Lilly repurchased roughly 16.9MM ($819MM) shares and plans to complete the remaining $1.1Bn of its share buyback program in 2013.”

Eli Lilly & Co. closed on Friday at $51.56.

Latest Ratings for LLY

DateFirmActionFromTo
Dec 2016Morgan StanleyUpgradesEqual-WeightOverweight
Nov 2016Atlantic EquitiesDowngradesOverweightNeutral
Nov 2016BMO CapitalDowngradesOutperformMarket Perform

View More Analyst Ratings for LLY
View the Latest Analyst Ratings

Posted-In: BMO Capital MarketsAnalyst Color Price Target Analyst Ratings

 

Related Articles (LLY)

View Comments and Join the Discussion!